FTC Lawsuit Against WPATH Over Transgender Treatment Guidelines
The organization recognized as a key authority on transgender healthcare, WPATH, is under scrutiny from the Federal Trade Commission (FTC) regarding its treatment guidelines for minors. Allegations suggest these guidelines were created with insufficient and uncertain evidence, which some of the organization’s leaders reportedly acknowledged privately.
The complaint, lodged in federal court in Texas by the FTC along with attorneys general from Alaska, Iowa, Nebraska, and Texas, claims WPATH developed influential guidance that healthcare providers follow when advising on puberty blockers, cross-sex hormones, and gender reassignment for minors.
This case may clarify whether the medical advice shaping transgender treatment for many young people was rooted in reliable evidence or merely influenced by a specific agenda. FTC Chairman Andrew Ferguson indicated that this is fundamentally a consumer protection issue revolving around whether families were given honest information about the advantages and risks involved with these medical interventions.
Ferguson stated, “Children, and especially their parents, must have complete and truthful information when making healthcare purchasing decisions.” He added that for decades the FTC has acted against organizations making unsubstantiated health claims.
Central to the lawsuit is the assertion that WPATH’s publicly stated standards of care are evidence-based, contrary to private admissions by its leadership regarding gaps in research. A 2023 memo from Eli Coleman, Ph.D., a lead author of WPATH’s eighth edition of standards, reportedly acknowledged these research gaps.
The complaint also highlighted comments from Dr. Amy Tichelman, lead author of WPATH’s chapter on children, who told NPR there is no established research base for evaluating or treating transgender youth effectively.
Furthermore, regulatory authorities allege that WPATH eliminated minimum age requirements for various procedures in their 2022 guidelines without the backing of scientific evidence. Some internal discussions indicated that WPATH’s leaders struggled to find evidence to justify these changes.
Kurt Miceli, chief medical officer at Do No Harm, emphasized that the allegations raise pressing questions on how the group’s guidelines were formed. He pointed out that conflicts of interest appear significant and often undisclosed.
Miceli stated, “WPATH appears to collaborate with individuals who have financial stakes in promoting pediatric transitions, generating guidelines that favor treatments including hormones and surgeries.”
Such influences from WPATH extend far beyond its members. Their standards are frequently referenced across medical fields, impacting treatment protocols and insurance policies throughout the U.S. Notably, WPATH plays a key role in the Endocrine Society’s widely used guidelines on gender dysphoria and gender nonconformity.
The lawsuit alleges that despite a lack of substantial evidence to support it, WPATH has represented pediatric transition treatments as “lifesaving.” For instance, there is a claim that parents were posed with a shocking choice: would they prefer a living daughter or a deceased son when considering treatment options for their child?
Miceli commented on troubling claims that WPATH promotes treatments without credible evidence. “The benefits they’re suggesting, in reality, are mostly non-existent, and the certainty surrounding these benefits is alarmingly low.”
According to the complaint, some minors who have undergone medical transitions have faced lasting complications, ranging from chronic pain to emotional distress.
In response to the lawsuit, WPATH dismissed the allegations, characterizing them as politically driven and legally unsound, asserting they have developed guidelines based on scientific standards and expert consensus for over 50 years.
Miceli expressed hope that the lawsuit could catalyze a more thorough review by healthcare organizations that have relied on WPATH’s standards. He urged renowned bodies like the American Medical Association and the American Academy of Pediatrics to reassess the evidence surrounding these guidelines immediately, emphasizing the need to prevent further harm caused by flawed care standards.
